Corcept Therapeutics Initiates CATALYST Clinical Trial
<!-- Name:DistributionId Value:8797160 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Nasdaq:CORT
Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral…
MENLO PARK, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications…
Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent,…
MENLO PARK, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications…
Corcept Therapeutics Announces Appointment of Three Senior Leaders
MENLO PARK, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to…
Corcept Therapeutics Completes Enrollment in Phase 2 GRATITUDE Study of Miricorilant…
MENLO PARK, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to…
Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Recurrent,…
Addition of relacorilant to nab-paclitaxel reduces risk of death by 33 percent compared to treatment with nab-paclitaxel alone (p-value: 0.066), without increased side effectsExcluding…
Corcept Therapeutics to Host Ovarian Cancer Program Update on Thursday, March 31,…
MENLO PARK, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will host an event for investors and analysts on Thursday, March…